235 related articles for article (PubMed ID: 25601866)
1. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
Front Immunol; 2014; 5():670. PubMed ID: 25601866
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
[TBL] [Abstract][Full Text] [Related]
3. The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab.
Wu B; Joshi A; Ren S; Ng C
J Pharm Sci; 2006 Jun; 95(6):1258-68. PubMed ID: 16637054
[TBL] [Abstract][Full Text] [Related]
4. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
8. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
9. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients.
Ng CM
Biopharm Drug Dispos; 2016 Mar; 37(2):107-19. PubMed ID: 26581439
[TBL] [Abstract][Full Text] [Related]
11. Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans.
Li T; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):714-724. PubMed ID: 30471293
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice.
Naoi S; Yamane M; Nemoto T; Kato M; Saito R; Tachibana T
Drug Metab Pharmacokinet; 2023 Dec; 53():100506. PubMed ID: 38029470
[TBL] [Abstract][Full Text] [Related]
14. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
15. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.
Pasquiers B; Benamara S; Felices M; Ternant D; Declèves X; Puszkiel A
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631343
[TBL] [Abstract][Full Text] [Related]
16. Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc Receptor (FcRn) in human tissues and implications for pharmacokinetic modelling.
Barber J; Al-Majdoub ZM; Couto N; Howard M; Elmorsi Y; Scotcher D; Alizai N; de Wildt S; Stader F; Sepp A; Rostami-Hodjegan A; Achour B
Eur J Pharm Sci; 2023 Mar; 182():106375. PubMed ID: 36626943
[TBL] [Abstract][Full Text] [Related]
17. Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.
Alqahtani S; Kaddoumi A
Clin Pharmacokinet; 2016 Aug; 55(8):957-69. PubMed ID: 26914771
[TBL] [Abstract][Full Text] [Related]
18. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.
Wong H; Chow TW
J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
